Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Clozaril Tablets 25 mg Temporarily in Short Supply due to Troubles at Overseas Plant
November 29, 2017
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
- Stefan Woxström Tapped as New AZ Japan President Effective Jan. 2018
November 28, 2017
- EA Pharma Files Constipation Drug AJG555 in Japan
November 28, 2017
- Santen Files Omidenepag Isopropyl for Glaucoma, Ocular Hypertension in Japan
November 28, 2017
- Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
- ASKA to Invest Management Resources Actively in New Drugs, Not Generics
November 27, 2017
- Takeda Spin-Off Chordia Concludes Investment Contract with Takeda, Venture Capitals
November 27, 2017
- Masamichi Terabatake to Be Appointed President of JT, Wants to “Steadily Invest” in Pharma Business
November 24, 2017
- Fuji Pharma Might Review Development Plans for Nesp Biosimilar Expecting Fierce Competition
November 24, 2017
- Daiichi Sankyo Begins PII Study of DS-8201 for Gastric Cancer in Japan, South Korea
November 22, 2017
- Mochida to Market Janssen’s Anticancer Agent Doxil in Japan
November 22, 2017
- Canalia Grabs GPs’ Attention in September: Anterio Ranking
November 21, 2017
- Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market
November 21, 2017
- Sales of 4 Top Wholesalers Down 0.2% in April-Sept. Following Decline in Demand for Hep C Drugs
November 21, 2017
- M3 Enters Regenerative Medicine Field, Investing 200 Million Yen in Biotech Firm
November 21, 2017
- Eisai’s Fycompa Available again in Germany from December following Reimbursement Price Settlement with Regulator
November 21, 2017
- 1st Patient Enrolled in PII/III for Healios’ Sakigake-Designated Stem Cell Therapy
November 17, 2017
- Maruho Exec Requests Discussions on Proper Use of Heparinoid Agents Based on “Appropriate Data,” Calls for Detailed Analysis of NDB
November 17, 2017
- Adcetris Gets European Panel Backing for CTCL: Takeda
November 16, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…